Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
A legfontosabb adatok
- Ki végzi
- Agiana Pharmaceuticals
- Hol
- Oslo (Norvégia)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 10 fő, tervezett
- Kezdés
- 2026. jan. 2.
- Várható befejezés
- 2027. jún. 30.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- AGP100
- A regiszteradat frissítve
- 2025. december 26.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with CPVT, an inherited heart rhythm disorder. They still have abnormal heartbeats during exercise despite stable heart medicine.
- Életkor
- 18 to 75 years
- Nem
- Male or female
- A betegség stádiuma
- Clinical diagnosis of CPVT. Repeated extra heartbeats or fast abnormal rhythms during exercise. At screening, extra heartbeats on a bicycle test (at least 1 point on the VA scale).
- Korábbi kezelés
- Must be on a stable, highest tolerated dose of a non-selective β-blocker for at least 4 weeks. A stable dose of flecainide for at least 4 weeks, added to the β-blocker, is also allowed.
- Biomarker vagy leletérték
- Proven RYR2 mutation.
A részvétel fő kizáró okai
- Structural heart disease, such as coronary artery disease or heart failure with ejection fraction <45%
- Dangerous rhythms causing unstable circulation at earlier exercise tests, or sustained VT (VA score of 5) at screening
- Other antiarrhythmic drugs except flecainide and non-selective β-blockers, or use of PDE3, PDE4 or PDE5 inhibitors
- High blood pressure: systolic >160 mmHg and/or diastolic >95 mmHg
- Pregnant or breastfeeding women, or PR >240 ms or QTc >480 ms at screening
A regiszter feltételei, szó szerint
Mind a 19 feltétel megnézéseKevesebb
Ki vehet részt
- Signed informed consent prior to any study-related procedures
- Male or female, aged between 18 and 75 years (inclusive)
- Clinical diagnosis of CPVT based on proven RYR2 mutation AND reproducible premature ventricular contraction with exercise or polymorphic or bidirectional ventricular tachycardia with exercise
- Able and willing to undergo exercise testing (bicycle test) AND exhibits exercise-induced ventricular ectopic beats at Screening (at least 1 point on the VA scale)
- On stable, maximum tolerated, dose of non-selective β-blocker for at least 4 weeks before Visit 1. The dosage and choice of β-blocker are to be determined by the patients' physician(s) before entry into the study and must remain unchanged throughout the conduct of the study. Participants taking a stable dose of flecainide for at least 4 weeks, in addition to β-blocker, are also eligible
- Clinical laboratory evaluations including clinical chemistry, haematology, urinalysis, thyroid function (including thyroid stimulating hormone, triiodothyronine, thyroxine, and free T4) and coagulation testing (activated partial thromboplastin time, and international normalized ratio) within the reference range, unless deemed not clinically significant by the Investigator
- Willing to refrain from strenuous or new exercise for 24 hours before each study visit
- Women of childbearing potential (WOCBP) agree to implement accepted and highly effective means of contraception from study entry until at least 33 days after study drug discontinuation (as per the Clinical Trials Facilitation and Coordination Group guidelines); The main exclusion criteria are:
- Diagnosis of structural heart disease, including coronary artery disease or heart failure with reduced ejection fraction (left ventricular ejection fraction <45%)
- Participants who have had arrhythmias causing hemodynamic instability at previous exercise tests (performed while on the current standard of care treatment)
- Participants having a sustained VT (VA score of 5) during the exercise tests performed as part of the screening activities
- Participation in another clinical study with an investigational product or device within 60 days of 5 half-lives prior to Baseline (whichever is longer)
- Medical history of severe anaphylactic reactions to any component(s) of the IMP
- Sensitivity to any of the study treatments, or components thereof, or any drug or other allergy that, in the opinion of the Investigator precludes participation in the study
- Hypersensitivity or contraindication to PDE2 inhibitor drugs
- Use of PDE3, PDE4, or PDE5 inhibitor drugs
- Participants taking any antiarrhythmic drug(s) except flecainide and non-selective β-blockers
- Significant hypertension (defined as systolic blood pressure of >160 mmHg and/or diastolic blood pressure of >95 mmHg). If the blood pressure results are out of range at Screening, the measurements can be repeated on the same day more than once, or at another convenient visit
- Prolonged PR and/or QTc interval at Screening, defined as PR >240 ms or QTc >480 ms
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 75 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Norvégia.
- Oslo University Hospital HFOslo, NorvégiaRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
This trial is conducted in patients with an inherited heart rhythm disorder called catecholaminergic polymorphic ventricular tachycardia (CPVT). This condition causes the heart to beat dangerously fast during situations of physical or emotional stress. CPVT is a serious condition that can limit the length and quality of patients' lives. Current treatment does not always prevent the abnormal heart rhythms that can occur as part of CPVT during strenuous exercise or stress, so new and improved medications are needed.
A teljes eredeti leírásKevesebb
The main questions that the trial will answer are:
* How safe and tolerable is the drug AGP100; i.e, what medical problems do patients experience when taking the drug? * Does the drug help CPVT patients to maintain a normal heart rhythm while they are exercising? * How does the drug affect the levels of key heart cell signalling molecules?
Patients with a diagnosis of CPVT who are aged between 18 and 75 and experience abnormal heart rhythms during exercise, despite taking a stable dose of the medication(s) prescribed by their doctor for their CPVT can take part in this trial. Participants should have normal kidney and liver function and not have high blood pressure or a diagnosis of structural heart disease. Women who are pregnant or breastfeeding cannot take part in the study. Participants who may become pregnant (and their partners) need to use highly effective methods of contraception during the study and for 90 days after the study ends.
Participants will take part in the study for ten weeks. During this time, participants will be asked to take three different doses of the the drug (AGP100), as well as their normal heart medication. The drug is an oral capsule and each different dose will be taken once a day for 13 days. The study starts with participants taking a low dose for 2 weeks, then a medium dose and then a high dose. At each dose, participants will undergo a clinical examination, report any potential side effects and the treating doctor will investigate the safety, tolerability and side effects of AGP100. In total, participants will take AGP100 once a day for about six weeks. The last four weeks of the study will be a follow-up period where participants will not take AGP100.
During the study, participants will need to visit the hospital six times. The visits will be three outpatient appointments and three overnight stays.
A vizsgálat csoportja
- AGP100A vizsgált kezelés
Within this single arm, three doses levels are planned in an intra-patient dose-escalation design. These will be administered in sequential treatment periods: * Daily dose of 5 mg (1 x 5 mg capsule), oral route, for a planned duration of 13 days (starting dose) * Daily dose of 25 mg (1 x 25 mg capsule), oral route, for a planned duration of 13 days * Daily dose of 50 mg (2 x 25 mg capsules), oral route, for a planned duration of 13 days
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A Phase 2a Trial to Investigate Safety, Tolerability and Exploratory Clinical Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (PACE-CPVT)
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT07263139: ki vehet részt
- A regiszteradat frissítve
- 2025. december 26.